Molecule Information
General Information of the Molecule (ID: Mol01574)
Name |
hsa-miR-34a-5p
,Homo sapiens
|
||||
---|---|---|---|---|---|
Synonyms |
microRNA 34a
Click to Show/Hide
|
||||
Molecule Type |
Mature miRNA
|
||||
Sequence |
UGGCAGUGUCUUAGCUGGUUGU
Click to Show/Hide
|
||||
Ensembl ID | |||||
HGNC ID | |||||
Mature Accession | |||||
Click to Show/Hide the Complete Species Lineage | |||||
Type(s) of Resistant Mechanism of This Molecule
EADR: Epigenetic Alteration of DNA, RNA or Protein
Drug Resistance Data Categorized by Drug
Approved Drug(s)
5 drug(s) in total
Carboplatin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Disease Class: Osteosarcoma | [1] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Resistant Drug | Carboplatin | |||
Molecule Alteration | Expression | Up-regulation |
||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Annexin V-FITC/propidium iodide (PI) staining assay | |||
Mechanism Description | The miR34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene. | |||
Disease Class: Osteosarcoma | [2] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Resistant Drug | Carboplatin | |||
Molecule Alteration | Expression | Up-regulation |
||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Activation | hsa05200 | |
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
MEF2 signaling pathway | Regulation | hsa04013 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The down-regulation of CD117 mediated by miR-34a-5p might be one of the reasons for OS drug resistance. CD117 may also regulate other processes, including cell adhesion, differentiation and migration, which are significant for cancer development and treatment. |
Cisplatin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Disease Class: Osteosarcoma | [1], [3] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Resistant Drug | Cisplatin | |||
Molecule Alteration | Expression | Up-regulation |
||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | ATF2/ATF3/ATF4 signaling pathway | Inhibition | hsa04915 | |
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Annexin V-FITC/propidium iodide (PI) staining assay | |||
Mechanism Description | The miR34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene. And miR34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. | |||
Disease Class: Osteosarcoma | [2] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Resistant Drug | Cisplatin | |||
Molecule Alteration | Expression | Up-regulation |
||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Activation | hsa05200 | |
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
MEF2 signaling pathway | Regulation | hsa04013 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The down-regulation of CD117 mediated by miR-34a-5p might be one of the reasons for OS drug resistance. CD117 may also regulate other processes, including cell adhesion, differentiation and migration, which are significant for cancer development and treatment. |
Doxorubicin
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Disease Class: Osteosarcoma | [1], [3] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Resistant Drug | Doxorubicin | |||
Molecule Alteration | Expression | Up-regulation |
||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | ATF2/ATF3/ATF4 signaling pathway | Inhibition | hsa04915 | |
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Annexin V-FITC/propidium iodide (PI) staining assay | |||
Mechanism Description | The miR34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene. And miR34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. | |||
Disease Class: Osteosarcoma | [2] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Resistant Drug | Doxorubicin | |||
Molecule Alteration | Expression | Up-regulation |
||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Activation | hsa05200 | |
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
MEF2 signaling pathway | Regulation | hsa04013 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The down-regulation of CD117 mediated by miR-34a-5p might be one of the reasons for OS drug resistance. CD117 may also regulate other processes, including cell adhesion, differentiation and migration, which are significant for cancer development and treatment. |
Etoposide
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Disease Class: Osteosarcoma | [1], [3] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Resistant Drug | Etoposide | |||
Molecule Alteration | Expression | Up-regulation |
||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | ATF2/ATF3/ATF4 signaling pathway | Inhibition | hsa04915 | |
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay; Annexin V-FITC/propidium iodide (PI) staining assay | |||
Mechanism Description | The miR34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene. And miR34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. | |||
Disease Class: Osteosarcoma | [2] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Resistant Drug | Etoposide | |||
Molecule Alteration | Expression | Up-regulation |
||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Activation | hsa05200 | |
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
MEF2 signaling pathway | Regulation | hsa04013 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The down-regulation of CD117 mediated by miR-34a-5p might be one of the reasons for OS drug resistance. CD117 may also regulate other processes, including cell adhesion, differentiation and migration, which are significant for cancer development and treatment. |
Methotrexate
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Disease Class: Osteosarcoma | [3] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Resistant Drug | Methotrexate | |||
Molecule Alteration | Expression | Up-regulation |
||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | ATF2/ATF3/ATF4 signaling pathway | Inhibition | hsa04915 | |
In Vitro Model | G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
IC50 assay; Flow cytometric analysis | |||
Mechanism Description | miR34a-5p promotes multi-chemoresistance of osteosarcoma through down-regulation of the DLL1 gene. The activity of the ATF2/ATF3/ATF4 pathway was reduced in the miR34a-5p mimic-transfected G-292 cells but increased in the miR34a-5p antagomiRtransfected SJSA-1 cells, hence the ATF2/ATF3/ATF4 pathway was validated to be involved in the OS chemoresistance mediated by miR34a-5p. | |||
Disease Class: Osteosarcoma | [2] | |||
Resistant Disease | Osteosarcoma [ICD-11: 2B51.0] | |||
Resistant Drug | Methotrexate | |||
Molecule Alteration | Expression | Up-regulation |
||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell invasion | Activation | hsa05200 | |
Cell migration | Activation | hsa04670 | ||
Cell proliferation | Activation | hsa05200 | ||
MEF2 signaling pathway | Regulation | hsa04013 | ||
In Vitro Model | MG63 cells | Bone marrow | Homo sapiens (Human) | CVCL_0426 |
SAOS-2 cells | Bone marrow | Homo sapiens (Human) | CVCL_0548 | |
U2OS cells | Bone | Homo sapiens (Human) | CVCL_0042 | |
G-292 cells | Bone | Homo sapiens (Human) | CVCL_2909 | |
SJSA-1 cells | Bone | Homo sapiens (Human) | CVCL_1697 | |
MG63.2 cells | Bone | Homo sapiens (Human) | CVCL_R705 | |
MNNG/HOS cells | Bone | Homo sapiens (Human) | CVCL_0439 | |
Experiment for Molecule Alteration |
qRT-PCR | |||
Experiment for Drug Resistance |
MTT assay | |||
Mechanism Description | The down-regulation of CD117 mediated by miR-34a-5p might be one of the reasons for OS drug resistance. CD117 may also regulate other processes, including cell adhesion, differentiation and migration, which are significant for cancer development and treatment. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.